PMID- 33023239
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 19
DP  - 2020 Oct 2
TI  - Role of Human Leukocyte Antigen System as A Predictive Biomarker for 
      Checkpoint-Based Immunotherapy in Cancer Patients.
LID - 10.3390/ijms21197295 [doi]
LID - 7295
AB  - Recent advances in cancer immunotherapy have clearly shown that checkpoint-based 
      immunotherapy is effective in a small subgroup of cancer patients. However, no 
      effective predictive biomarker has been identified so far. The major 
      histocompatibility complex, better known in humans as human leukocyte antigen 
      (HLA), is a very polymorphic gene complex consisting of more than 200 genes. It 
      has a crucial role in activating an appropriate host immune response against 
      pathogens and tumor cells by discriminating self and non-self peptides. Several 
      lines of evidence have shown that down-regulation of expression of HLA class I 
      antigen derived peptide complexes by cancer cells is a mechanism of tumor immune 
      escape and is often associated to poor prognosis in cancer patients. In addition, 
      it has also been shown that HLA class I and II antigen expression, as well as 
      defects in the antigen processing machinery complex, may predict tumor responses 
      in cancer immunotherapy. Nevertheless, the role of HLA in predicting tumor 
      responses to checkpoint-based immunotherapy is still debated. In this review, 
      firstly, we will describe the structure and function of the HLA system. Secondly, 
      we will summarize the HLA defects and their clinical significance in cancer 
      patients. Thirdly, we will review the potential role of the HLA as a predictive 
      biomarker for checkpoint-based immunotherapy in cancer patients. Lastly, we will 
      discuss the potential strategies that may restore HLA function to implement novel 
      therapeutic strategies in cancer patients.
FAU - Sabbatino, Francesco
AU  - Sabbatino F
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
AD  - Oncology Unit, AOU San Giovanni di Dio e Ruggi D'Aragona, 84131 Salerno, Italy.
FAU - Liguori, Luigi
AU  - Liguori L
AD  - Department of Clinical Medicine and Surgery, University of Naples "Federico II", 
      80131 Naples, Italy.
FAU - Polcaro, Giovanna
AU  - Polcaro G
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
FAU - Salvato, Ilaria
AU  - Salvato I
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
AD  - Pulmonary Unit, Department of Biomedical Sciences, Dentistry, Morphological and 
      Functional Imaging (BIOMORF), University of Messina, 98125 Messina, Italy.
FAU - Caramori, Gaetano
AU  - Caramori G
AD  - Pulmonary Unit, Department of Biomedical Sciences, Dentistry, Morphological and 
      Functional Imaging (BIOMORF), University of Messina, 98125 Messina, Italy.
FAU - Salzano, Francesco A
AU  - Salzano FA
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
FAU - Casolaro, Vincenzo
AU  - Casolaro V
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
FAU - Stellato, Cristiana
AU  - Stellato C
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
FAU - Col, Jessica Dal
AU  - Col JD
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
FAU - Pepe, Stefano
AU  - Pepe S
AD  - Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', 
      University of Salerno, 84081 Baronissi, Salerno, Italy.
AD  - Oncology Unit, AOU San Giovanni di Dio e Ruggi D'Aragona, 84131 Salerno, Italy.
LA  - eng
GR  - 2017PHRC8X_003/Ministero dell'Istruzione, dell'Universita e della Ricerca/
GR  - Brains2South 2015 PDR-0224/Fondazione CON IL SUD/
PT  - Journal Article
PT  - Review
DEP - 20201002
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Antigen Presentation/immunology
MH  - Biomarkers, Tumor/genetics/*immunology
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Neoplasms/genetics/*immunology/therapy
MH  - Tumor Escape/immunology
PMC - PMC7582904
OTO - NOTNLM
OT  - biomarker
OT  - cancer immunotherapy
OT  - carcinogenesis
OT  - major histocompatibility complex (MHC), human leukocyte antigen (HLA), antigen 
      processing machinery (APM) molecules
OT  - tumor predisposition
COIS- The authors declare no conflict of interest.
EDAT- 2020/10/08 06:00
MHDA- 2021/02/27 06:00
PMCR- 2020/10/01
CRDT- 2020/10/07 01:02
PHST- 2020/08/20 00:00 [received]
PHST- 2020/09/26 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/07 01:02 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - ijms21197295 [pii]
AID - ijms-21-07295 [pii]
AID - 10.3390/ijms21197295 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Oct 2;21(19):7295. doi: 10.3390/ijms21197295.